Steven M. Corsello

Assistant Professor at Chemical and Systems Biology, Stanford University0 Followers

Dr. Steven M. Corsello is internationally recognized for his pioneering work in the field of oncology and chemical biology. As an Assistant Professor of Medicine (Oncology) and Chemical and Systems Biology at Stanford University, Dr. Corsello has made significant contributions to understanding and combating cancer. His research is at the forefront of integrating functional genomics with chemical biology to discover and develop new cancer-fighting mechanisms. Dr. Corsello's innovative approach involves utilizing phenotypic screening and functional genomics to identify novel anti-cancer mechanisms of small molecules. This work is particularly focused on developing targeted therapies for solid tumors, which remain a challenging area in cancer treatment. By leveraging these advanced techniques, his team aims to uncover new pathways and targets that can be exploited for therapeutic intervention. His dedication and groundbreaking research have earned him accolades from the scientific community, including the prestigious 2023 Shmunis Family Innovation Award in Cancer Therapeutics from the Stanford Cancer Institute. This recognition underscores his commitment to advancing cancer research and developing effective therapies that can improve patient outcomes. In addition to his research, Dr. Corsello is deeply involved in mentoring the next generation of scientists and clinicians. He is passionate about fostering a collaborative and innovative research environment that encourages creativity and critical thinking. His work not only contributes to the scientific understanding of cancer biology but also holds promise for translating these findings into clinical applications that can benefit patients worldwide. Dr. Corsello's contributions to the field of cancer biology and his commitment to translational research make him a leading figure in the fight against cancer. His work continues to inspire and drive progress in the development of targeted therapies, offering hope for more effective treatments for solid tumors.

External Link

Research Interests

Cancer biology Anti-cancer mechanisms Targeted therapies Solid tumors Chemical biology Functional genomics Phenotypic screening Small molecules

Publications

1 - Abstract PR009: RNF43 G659fs is an oncogenic and immune-modulating colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition,Cancer Research

Marios Giannakis , Lishan Fang , Dane Ford-Roshon , Max Russo , Casey O'Brien , Xiaozhe Xiong , Carino Gurjao , Maximilien Grandclaudon , Srivatsan Raghavan , Steven M. Corsello , Steven A. Carr , Namrata Udeshi , James Berstler , Ewa Sicinska , Kimmie Ng ,

, PR009-PR009, 2022-12-01

2 - Abstract A132: Characterization of intratumoral heterogeneity in drug sensitivity and non-cell autonomous mechanisms of drug resistance using subclonal cell populations derived from a single breast cancer cell line,Molecular Cancer Therapeutics

Chandler M Friend , Joan S Brugge , Hendrik J Kuiken , Steven M Corsello , Christopher C Mader ,

, A132-A132, 2019-12-01

3 - Abstract 3775: Characterization of intratumoral heterogeneity in drug sensitivity and modeling of drug combination effects using subclonal cell populations derived from a single breast cancer cell line,Cancer Research

Hendrik J. Kuiken , Chandler M. Friend , Steven M. Corsello , Christopher C. Mader , Joan S. Brugge ,

, 3775-3775, 2019-07-01

4 - Abstract 960: RNF43 G659fs is an oncogenic mutation in colorectal cancer and sensitizes tumor cells to PI3K/mTOR inhibition,Cancer Research

Lishan Fang , Dane Ford-Roshon , Max Russo , Casey O'Brien , Carino Gurjao , Maximilien Grandclaudon , Steven M. Corsello , Srivatsan Raghavan , Namrata Udeshi , James Berstler , Ewa Sicinska , Kimmie Ng , Marios Giannakis ,

, 960-960, 2021-07-01

5 - Abstract PR11: Reference pharmacologic class analysis for Connectivity Map discovery,Cancer Research

Steven M. Corsello , Rajiv Narayan , Joshua Gould , Ted E. Natoli , Xiaodong Lu , Aravind Subramanian , Todd R. Golub ,

, PR11-PR11, 2015-11-15

6 - Abstract A2-26: Reference pharmacologic class analysis for Connectivity Map discovery,Cancer Research

Steven M. Corsello , Rajiv Narayan , Joshua Gould , Ted E. Natoli , Xiaodong Lu , Aravind Subramanian , Todd R. Golub ,

, A2-26-A2-26, 2015-11-15

7 - Abstract 3400: Adenosine receptor antagonists exhibit potent and selective off-target killing of FOXA1-high cancers,Cancer Research

Steven M. Corsello , Ryan D. Spangler , Ranad Humeidi , Caitlin N. Harrington , Rohith T. Nagari , Ritu Singh , Vickie Wang , Mustafa Kocak , Jordan Rossen , Amael Madec , Nancy Dumont , Todd R. Golub ,

, 3400-3400, 2020-08-15

8 - Modulating AML1-ETO with Signature-Based Small Molecule Library Screening.,Blood

Kimberly Stegmaier , Steven M. Corsello , Kenneth N. Ross , Todd R. Golub ,

, 729-729, 2006-11-16

9 - Modernizing the NCI60 Cell Line Screen for Phenotypic Drug Discovery in the 21st Century,Cancer Research

Gianna M. Colombo , Steven M. Corsello ,

, 2397-2399, 2024-08-01

10 - Identification of AML1-ETO modulators by chemical genomics,Blood

Steven M. Corsello , Giovanni Roti , Kenneth N. Ross , Kwan T. Chow , Ilene Galinsky , Daniel J. DeAngelo , Richard M. Stone , Andrew L. Kung , Todd R. Golub , Kimberly Stegmaier ,

, 6193-6205, 2009-06-11

11 - RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition,Nature Communications

Lishan Fang , Dane Ford-Roshon , Max Russo , Casey O’Brien , Xiaozhe Xiong , Carino Gurjao , Maximilien Grandclaudon , Srivatsan Raghavan , Steven M. Corsello , Steven A. Carr , Namrata D. Udeshi , James Berstler , Ewa Sicinska , Kimmie Ng , Marios Giannakis ,

, 2022-06-08

12 - Gefitinib induces myeloid differentiation of acute myeloid leukemia,Blood

Kimberly Stegmaier , Steven M. Corsello , Kenneth N. Ross , Jenny S. Wong , Daniel J. DeAngelo , Todd R. Golub ,

, 2841-2848, 2005-10-15

13 - Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?,Nature Clinical Practice Urology

Steven M Corsello , Philip W Kantoff ,

, 80-81, 2007-12-18

14 - Anticoagulation Issues in Oncology,Cancer Consult: Expertise for Clinical Practice

Steven M. Corsello , Jean Marie Connors ,

, 844-850, 2014-06-20

15 - Abstract 3775: Characterization of intratumoral heterogeneity in drug sensitivity and modeling of drug combination effects using subclonal cell populations derived from a single breast cancer cell line,Tumor Biology

Hendrik J. Kuiken , Chandler M. Friend , Steven M. Corsello , Christopher C. Mader , Joan S. Brugge ,

, 3775-3775, 2019-07-01

Share Steven's Profile

Stanford University

Stanford, CA

Stanford University is a private research university located in Stanford, California. Founded in 1885 by Leland and Jane Stanford, the university has grown to become one of the most prestigious universities in the world. Stanford is consistently ranked among the top universities in the world by major publications such as U.S. News & World Report and Times Higher Education.

controlPrivate

Ranked 3

Admission Rate4%

Enrollment 7645

Learn More

Chemical and Systems Biology

Stanford University

Chemical and Systems Biology at Stanford University resides within the School of Medicine, specifically within the Department of Biochemistry. It represents a convergence of disciplines, employing tools from chemistry, biology, physics, mathematics, and computer science to unravel the complexities of biological systems. Its core lies in understanding the intricate networks of interactions within cells and organisms, offering insights into fundamental life processes and disease mechanisms. The program emphasizes a quantitative approach, leveraging cutting-edge technologies like high-throughput screening, genomics, proteomics, and advanced imaging to delve into biological phenomena at a molecular level.

Learn More